Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

The Lancet Oncology - Tập 11 Số 8 - Trang 753-762 - 2010
Wendy De Roock1, Bart Claes2, David Bernasconi3, Jef De Schutter1, Bart Biesmans1, George Fountzilas4, Konstantine T. Kalogeras4, Vassiliki Kotoula4, Demetris Papamichael5, Pierre Laurent‐Puig6, Frédérique Penault-Llorca7, Philippe Rougier8, Bruno Vincenzi9, Daniele Santini9, Giuseppe Tonini9, Federico Cappuzzo10, Milo Frattini11, Francesca Molinari11, Piercarlo Saletti12, Sara De Dosso12, Miriam Martini13, Alberto Bardelli13, Salvatore Siena14, Andrea Sartore‐Bianchi14, Josep Tabernero15, Teresa Macarulla15, Frédéric Di Fiore16, Alice Gangloff16, Fortunato Ciardiello17, Per Pfeiffer18, Camilla Qvortrup18, Tine Plato Hansen19, Eric Van Cutsem20, Hubert Piessevaux21, Diether Lambrechts2, Mauro Delorenzi22,3, Sabine Tejpar20
1Centre for Human Genetics, KU Leuven, Leuven, Belgium
2Vesalius Research Centre, KU Leuven and VIB, Leuven, Belgium
3Swiss Institute of Bioinformatics, Lausanne, Switzerland
4Hellenic Cooperative Oncology Group (HeCOG) and Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
5B O Cyprus Oncology Centre, Nicosia, Cyprus
6Université Paris Descartes, INSERM UMR-S775, Paris, France
7Departement de Pathologie, Centre De Lutte Contre le Cancer Jean Perrin and Equipe d'accueil EA 4233, Université d'Auvergne, Clermont-Ferrand, France
8Assistance Publique Hôpitaux Paris, Hôpital Ambroise Paré, Boulogne Billancourt, France
9Medical Oncology University Campus Bio-Medico of Rome, Italy
10Division of Medical Oncology, Ospedale Civile, Livorno, Italy
11Laboratory of Molecular Diagnostic, Institute of Pathology, Locarno, Switzerland
12Oncology Institute of Southern Switzerland, San Giovanni Hospital, Bellinzona, Switzerland
13Laboratory of Molecular Genetics, Institute for Cancer Research and Treatment, University of Turin Medical School, Candiolo, Turin, Italy
14The Falck Division of Medical Oncology, Ospedale Niguarda Ca’ Granda, Milan, Italy
15Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain
16Inserm U614, Faculty of Medicine, Institute for Biomedical Research, Rouen, France
17Division of Medical Oncology, Department of Experimental and Clinical Medicine, Second University of Naples, Italy
18Department of Oncology, Odense University Hospital and Institute of Clinical Research, University of Southern Denmark, Denmark
19Department of Pathology, Odense University Hospital, Denmark
20Department of Digestive Oncology, University Hospital Gasthuisberg, KU Leuven, Leuven, Belgium
21Service de Gastro-entérologie, Cliniques Universitaires Saint-Luc, UCL, Brussels, Belgium
22Département de Formation et Recherche, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland

Tóm tắt

Từ khóa


Tài liệu tham khảo

Cunningham, 2004, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer, N Engl J Med, 351, 337, 10.1056/NEJMoa033025

Amado, 2008, Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer, J Clin Oncol, 26, 1626, 10.1200/JCO.2007.14.7116

Karapetis, 2008, K-ras mutations and benefit from cetuximab in advanced colorectal cancer, N Engl J Med, 35, 757

Allegra, 2009, American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy, J Clin Oncol, 27, 2091, 10.1200/JCO.2009.21.9170

Sartore-Bianchi, 2009, Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer, PLoS One, 4, e7287, 10.1371/journal.pone.0007287

Laurent-Puig, 2009, Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer, J Clin Oncol, 27, 5924, 10.1200/JCO.2008.21.6796

De Roock, 2009, K-ras mutations and cetuximab in colorectal cancer, N Engl J Med, 360, 834

Piessevaux, 2009, Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial), Ann Oncol, 20, 1375, 10.1093/annonc/mdp011

Downward, 2003, Targeting RAS signalling pathways in cancer therapy, Nat Rev Cancer, 3, 11, 10.1038/nrc969

Hothorn, 2006, Unbiased recursive partitioning: a conditional inference framework, J Comput Graph Stat, 15, 651, 10.1198/106186006X133933

Ogino, 2009, PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer, J Clin Oncol, 27, 1477, 10.1200/JCO.2008.18.6544

Barault, 2008, Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers, Int J Cancer, 122, 2255, 10.1002/ijc.23388

Souglakos, 2009, Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer, Br J Cancer, 101, 465, 10.1038/sj.bjc.6605164

Zhao, 2008, Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms, Proc Natl Acad Sci USA, 105, 2652, 10.1073/pnas.0712169105

Kalinsky, 2009, PIK3CA mutation associates with improved outcome in breast cancer, Clin Canc Res, 15, 5049, 10.1158/1078-0432.CCR-09-0632

Lai, 2008, PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients, Ann Surg Oncol, 15, 1064, 10.1245/s10434-007-9751-7

Normanno, 2009, Implications for KRAS status and EGFR-targeted therapies in metastatic CRC, Nat Rev Clin Oncol, 6, 519, 10.1038/nrclinonc.2009.111

Bardelli, 2010, Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer, J Clin Oncol, 28, 1254, 10.1200/JCO.2009.24.6116

Loupakis, 2009, KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer, Br J Cancer, 101, 715, 10.1038/sj.bjc.6605177

Sartore-Bianchi, 2009, PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies, Cancer Res, 69, 1851, 10.1158/0008-5472.CAN-08-2466

Prenen, 2009, PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer, Clin Cancer Res, 15, 3184, 10.1158/1078-0432.CCR-08-2961

Smalley, 2009, CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations, Oncogene, 28, 85, 10.1038/onc.2008.362

Richman, 2009, KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial, J Clin Oncol, 27, 5931, 10.1200/JCO.2009.22.4295

Van Cutsem, 2010, Cetuximab plus FOLFIRI: final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome, J Clin Oncol, 28

Roth, 2010, Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial, J Clin Oncol, 28, 466, 10.1200/JCO.2009.23.3452

Peeters M, Oliner KS, Parker A, et al. Use of massively parallel, next-generation sequencing to identify gene mutations beyond KRAS that predict response to panitumumab in a randomized, phase 3, monotherapy study of metastatic colorectal cancer (mCRC). 2010 American Association for Cancer Research 101st Annual Meeting, Washington, DC, USA; April 17–21: abstr LB-174.

Moroni, 2005, Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study, Lancet Oncol, 6, 279, 10.1016/S1470-2045(05)70102-9

Personeni, 2008, Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with Cetuximab: a fluorescent in situ hybridization study, Clin Cancer Res, 14, 5869, 10.1158/1078-0432.CCR-08-0449

Jacobs, 2009, Amphiregulin and Epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab, J Clin Oncol, 27, 5068, 10.1200/JCO.2008.21.3744

Tabernero, 2010, Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study, J Clin Oncol, 28, 1181, 10.1200/JCO.2009.22.6043

Zhang, 2007, FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab, J Clin Oncol, 25, 3712, 10.1200/JCO.2006.08.8021

Lurje, 2008, Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab, Clin Cancer Res, 14, 7884, 10.1158/1078-0432.CCR-07-5165

Bibeau, 2009, Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan, J Clin Oncol, 27, 1122, 10.1200/JCO.2008.18.0463

Thông tin
Thông tin xuất bản

The Lancet Oncology

Tập 11 Số 8

753-762

Thông tin tác giả